(Reuters) - Data presented on Saturday at the American Society of
Clinical Oncology annual meeting in Chicago found improvement
in 27 percent of patients after 12 weeks on pazopanib, which
starves tumors of their blood supply.
Another 46 percent of patients had their disease stabilize
-- a very positive sign for patients with a usually hopeless cancer.
Read more at Reuters.com Government Filings News
Clinical Oncology annual meeting in Chicago found improvement
in 27 percent of patients after 12 weeks on pazopanib, which
starves tumors of their blood supply.
Another 46 percent of patients had their disease stabilize
-- a very positive sign for patients with a usually hopeless cancer.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment